Allurion Technologies, Inc. (ALUR)

Allurion Technologies, Inc. experienced a significant price decline of 88.21% between January 2, 2025, and December 31, 2025. A 1-for-25 reverse stock split was announced on December 24, 2024, and became effective on January 3, 2025. The company reported third-quarter 2025 earnings that surpassed analyst expectations on November 14, 2025. Allurion Technologies Inc. announced a delayed 10-Q filing on November 18, 2025. Analysts decreased the price target for ALUR on November 14, 2025, and October 29, 2025. The company passed critical FDA milestones on November 11, 2025. Allurion announced preliminary results for the fourth quarter and full year 2025 on January 12, 2026, showing revenue increase and improvement in operating expenses. A director of Allurion Technologies sold shares on December 5, 2025. The submission of the first three modules of its premarket approval (PMA) application to the FDA for the Allurion Balloon was announced on October 24, 2024. Allurion Technologies Inc. completed a Follow-on Equity Offering in February 2025, raising $4.707 million. Q1 2025 revenue was negatively impacted by a temporary suspension of sales in France and reduced sales and marketing investments, and Q3 2024 revenue also saw a reduction due to a product recall in France and the temporary suspension of the Allurion Balloon.

Information regarding the specific demand seasonality for Allurion Technologies, Inc.'s products and services is not readily available in the provided search results.

Allurion Technologies, Inc. is a medical technology company focused on combating obesity through its weight loss platform, operating in the Health Technology sector, specifically in Medical Specialties and Medical Products. The company's primary offering is the Allurion Program, featuring the Allurion Gastric Balloon, a swallowable, procedure-less intragastric balloon that doesn't require surgery, endoscopy, or anesthesia for placement or removal. The program also includes the Allurion Virtual Care Suite, comprising the Allurion Mobile App, Allurion Insights, and health tracker devices.

Allurion Technologies, Inc. is headquartered in Natick, Massachusetts, United States, and has an international presence, including operations in countries such as Spain, France, and Turkey. The Allurion Balloon is currently an investigational device in the United States and is not yet approved for use there.

Allurion Technologies' brand reputation has been influenced by both positive developments and challenges. The company positions itself as a pioneer in metabolically healthy weight loss, contributing to a positive brand image. Positive news includes the successful treatment of the last patient in its pivotal FDA AUDACITY trial and advancing its Virtual Care Suite. However, the brand's reputation has faced setbacks, particularly in France, due to a temporary suspension of the Allurion Balloon and a product recall.

Allurion Technologies Inc. has a notable ownership structure with significant insider and institutional holdings. Institutional shareholders own approximately 21.39% to 30.42% of the company's stock, with major holders including RTW Investments LP, UBS Group AG, and Vanguard Group Inc. Insiders hold a substantial 89.46% of Allurion Technologies' stock, with Omar Ishrak being the largest individual shareholder.